Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib

Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib

Tyrosine kinase inhibitors (TKIs) such as imatinib improve the prognosis of patients with gastrointestinal stromal tumors (GISTs). However, treatment options for GISTs are still limited, and the continuation of TKIs is difficult due to adverse events in some cases. The effectiveness of low-dose imat...

Full description

Bibliographic Details
Main Authors: Ryo Katsumata, Yasumasa Monobe, Yosuke Katata, Hideyo Fujiwara, Takashi Urano, Akihisa Akagi, Kotone Tsujimoto, Takako Konishi, Noriaki Manabe, Tomoari Kamada, Hirofumi Kawamoto, Tomoki Yamatsuji, Yoshio Naomoto
Format: Article
Language:English
Published: Karger Publishers 2023-02-01
Series:Case Reports in Gastroenterology
Subjects:
gastrointestinal stromal tumors
imatinib
exon 11 kit mutation
tyrosine kinase inhibitor
Online Access:https://www.karger.com/Article/FullText/529002

Internet

https://www.karger.com/Article/FullText/529002

Similar Items